Ensuring Affordable Drugs in the Private Market after BBB

After a delay, Congress is considering passing the most significant drug pricing legislation in a generation as part of the Build Back Better (BBB) legislative agenda. While much attention has focused on the BBB’s provisions relating to Medicare price negotiations, the legislation could have a significant impact on the future price of drugs for the more than 180 million people who receive health coverage through their employers or purchase it in the private market. Whether the BBB’s drug pricing provisions are ultimately enacted, the high cost of prescription drugs will remain a leading driver of health care spending for employers, purchasers, and consumers.

Join leading employer and purchaser representatives and national prescription drug policy experts for a roundtable discussion on the future of prescription drug policy after the BBB.

Areas of Discussion:

• How the BBB would impact the price of drugs in the commercial market
• How would drug makers and other actors in the supply chain react to enactment of the BBB?
• What else can employers and private purchasers do to moderate drug costs?
• Where should policymakers focus next?

Presenters and Panelists:

• Sean Dickson, Director of Health Policy, West Health Policy Center
• Richard Frank, Ph.D., Senior Fellow in Economic Studies, Brookings Institution
• James Gelfand, EVP for Public Affairs, the ERISA Industry Committee
• Desiree Hoffman, Assistant Legislative Director, United Auto Workers
• Elizabeth Mitchell, President and CEO, Purchaser Business Group on Health
• Mariana Socal, M.D., Associate Scientist, Johns Hopkins University

Recording: